行情

CYCC

CYCC

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

0.3857
+0.0104
+2.77%
已收盘, 16:00 03/31 EDT
开盘
0.3940
昨收
0.3753
最高
0.4000
最低
0.3753
成交量
6.62万
成交额
--
52周最高
1.020
52周最低
0.2813
市值
663.40万
市盈率(TTM)
-0.7782
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CYCC价格均价为6.50,最高价位7.00,最低价为6.00。

EPS

CYCC 新闻

更多
  • 特朗普据悉将宣布部分关税可延期90天缴纳
  • 新浪财经 · 2小时前
  • 黄金期货周二收跌2.8% 第一季度上涨4.8%
  • 新浪美股 · 2小时前
  • 尾盘:美股维持跌势 道指跌逾200点
  • 新浪美股 · 3小时前
  • “淘金热”给200亿美元ETF带来10年来最大规模资金流入
  • 新浪美股 · 3小时前

所属板块

生物技术和医学研究
-0.26%
制药与医学研究
-0.17%

热门股票

代码
价格
涨跌幅

CYCC 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

微牛提供Cyclacel Pharmaceuticals Inc(NASDAQ-CYCC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CYCC股票新闻,以帮助您做出投资决策。